Home
June 2009 July 2009 August 2009
Su Mo Tu We Th Fr Sa
Week 27 1 2 3 4
Week 28 5 6 7 8 9 10 11
Week 29 12 13 14 15 16 17 18
Week 30 19 20 21 22 23 24 25
Week 31 26 27 28 29 30 31

The Clinical Efficacy of Tolterodine Extended-Release is Maintained for 24 h in Patients with Overactive Bladder - Abstract Show Comments PDF Print E-mail
  
Friday, 17 August 2007
Department of Urology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. This email address is being protected from spam bots, you need Javascript enabled to view it

To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).

We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (> or =8 voids/24 h) and UUI (> or=5 episodes/week) for > or = 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.

Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.

These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.

Written by Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z.

Reference

BJU Int. 2007 Jul;100(1):107-10

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 

Bookmark and Share
< Prev   Next >

Member's Section

Login

Sign Up

Quick Search

Featured Conference

Complete WUF 2009 Coverage

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities

Overactive Bladder
Sponsored By